JAVELIN Medley
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
- NCT02554812 ↗
- Terminated
- Pfizer
- Standard
We haven't built an HCP commentary report on JAVELIN Medley (avelumab plus utomilumab; avelumab plus ivuxolimab (PF-04518600); avelumab plus PD 0360324 in advanced malignancies) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from all 15 indexed sources (Jan 2024 – Aug 2025). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether the combination improves overall survival
- How toxicity affects use in the maintenance setting
- Which patients may benefit, and whether biomarkers can identify them
- How the combination fits alongside current first-line therapy
Also discussed: Trop-2 targeting.
Indexed commentary on JAVELIN Medley so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 8 | |
| Podcasts | 6 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES
- Phase
- Phase 1/Phase 2
- Status
- Terminated
- Conditions
- Advanced Cancer
- Interventions
- Avelumab; Utomilumab; PF-04518600; PD 0360324; CMP-001
- Arms
- Cohort A1 · Experimental
- Cohort A2 · Experimental
- Cohort A3 · Experimental
- Cohort A4 · Experimental
- Cohort A5 · Experimental
- Cohort A6 · Experimental
- Cohort A7 · Experimental
- Cohort A8 · Experimental
- Combination B Dose Escalation · Experimental
- Combination B Expansion Cohorts · Experimental
- Combination C Dose escalation cohorts · Experimental
- Combination C Dose expansion cohorts · Experimental
- Combination D Dose escalation cohorts · Experimental
- Combination D Dose expansion cohorts · Experimental
- Cohort A9 · Experimental
- Cohort A10 · Experimental
- Cohort F1 · Experimental
- Cohort F2 · Experimental
- Cohort F3 · Experimental
- Enrollment
- 409
- Primary outcomes
- Phase 1b Lead-in: Number of Participants With First 2 Cycles Dose Limiting Toxicity (DLT) for Combination A
- Phase 1b Lead-in: Number of Participants With First 2 Cycles DLT for Combination B
- Phase 1b Lead-in: Number of Participants With First 2 Cycles DLT for Combination C
- Phase 1b Lead-in: Number of Participants With First 2 Cycles DLT for Combination D
- Phase 1b Lead-in: Number of Participants With First Cycle DLT for Combination F
- Phase 2: Percentage of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment for Combination A
- Phase 2: Percentage of Participants With Confirmed OR as Per RECIST v 1.1 by Investigator Assessment for Combination B
- Sponsor
- Pfizer
- Start
- Nov 9, 2015
- Primary completion
- Mar 23, 2023
- Results posted
- Yes
- Registry record
- NCT02554812 · updated Jul 30, 2024